Tetra Bio-Pharma Inc. through its subsidiary unit, PhytoPain Pharma Inc. has signed a Supply deal with ACMPR licensed producer Aphria Inc. (OTCMKTS:APHQF). This deal is pertaining to the distribution of dried medical cannabis as an API for PhytoPain’s inhalation cannabis offering ‘PPP001’. PPP001 is stated as a medical marijuana offering that the firm is advancing as a prescription controlled medication for inhalation utilizing a fully assembled titanium pipe.
The highlights
Aphria is an approved producer under the ACMPR. Under the reported supply deal, PhytoPain shall pursue the advancement of a prescription controlled inhalation medication offering of medical marijuana and get marketing nod across the globe either indirectly or directly through licensing agreements or partnerships. The company will be the exclusive dealer of this API to PhytoPain for the commercialization and advancement of PP001.
PPP is given a limited, non-transferrable, royalty free, license to utilize the API in the advancement of PPP001. The deal highlights a purchase price in the clinical advancement and a volume rebate after target volume is touched.
Both USA and Canadian prescription drug guidelines enforce rigorous quality systems for the manufacturing of the finished drug product and API. These requirements comprise conformance to pharmaceutical GMP as well as showcasing the ability of the manufacturer to confirm lot-to-lot consistency in the safety and quality of the prescription drug.
The expert view
Dr. Guy Chamberland, M.Sc., Ph.D., the Chief Scientific Officer of PhytoPain, said that they are extremely excited and pleased to be working with Aphria in the advancement of PPP001. Advancing prescription botanical based medications needs a high quality GMP system and established product specifications to get consistent efficacy and finally get the patients safety. Based on the evaluation of company, they are confident that their premium GMP medical marijuana production facility and notable quality assurance team will exceed or meet the expectations of both the USA and Canadian prescription drug authorities.
